Literature DB >> 19220984

Characterization of human corneal epithelial cell model as a surrogate for corneal permeability assessment: metabolism and transport.

Cathie D Xiang1, Minerva Batugo, David C Gale, Tao Zhang, Jingjing Ye, Chunze Li, Sue Zhou, Ellen Y Wu, Eric Y Zhang.   

Abstract

The recently introduced Clonetics human corneal epithelium (cHCE) cell line is considered a promising in vitro permeability model, replacing excised animal cornea to predict corneal permeability of topically administered compounds. The purpose of this study was to further characterize cHCE as a corneal permeability model from both drug metabolism and transport aspects. First, good correlation was found in the permeability values (P(app)) obtained from cHCE and rabbit corneas for various ophthalmic drugs and permeability markers. Second, a previously established real-time quantitative polymerase chain reaction method was used to profile mRNA expression of drug-metabolizing enzymes (major cytochromes P450 and UDP glucuronosyltransferase 1A1) and transporters in cHCE in comparison with human cornea. Findings indicated that 1) the mRNA expression of most metabolizing enzymes tested was lower in cHCE than in excised human cornea, 2) the mRNA expression of efflux transporters [multidrug resistant-associated protein (MRP) 1, MRP2, MRP3, and breast cancer resistance protein], peptide transporters (PEPT1 and PEPT2), and organic cation transporters (OCTN1, OCTN2, OCT1, and OCT3) could be detected in cHCE as in human cornea. However, multidrug resistance (MDR) 1 and organic anion transporting polypeptide 2B1 was not detected in cHCE; 3) cHCE was demonstrated to possess both esterase and ketone reductase activities known to be present in human cornea; and 4) transport studies using probe substrates suggested that both active efflux and uptake transport may be limited in cHCE. As the first detailed report to delineate drug metabolism and transport characteristics of cHCE, this work shed light on the usefulness and potential limitations of cHCE in predicting the corneal permeability of ophthalmic drugs, including ester prodrugs, and transporter substrates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19220984     DOI: 10.1124/dmd.108.026286

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  18 in total

Review 1.  Ocular drug delivery.

Authors:  Ripal Gaudana; Hari Krishna Ananthula; Ashwin Parenky; Ashim K Mitra
Journal:  AAPS J       Date:  2010-05-01       Impact factor: 4.009

2.  Cytotoxicity assays of new artificial tears containing 2-methacryloyloxyethyl phosphorylcholine polymer for ocular surface cells.

Authors:  Masahiko Ayaki; Atsuo Iwasawa; Yoshimi Niwano
Journal:  Jpn J Ophthalmol       Date:  2011-08-10       Impact factor: 2.447

Review 3.  In vitro and ex vivo corneal penetration and absorption models.

Authors:  Priyanka Agarwal; Ilva D Rupenthal
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

4.  Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.

Authors:  Kishore Cholkar; Hoang M Trinh; Aswani Dutt Vadlapudi; Zhiying Wang; Dhananjay Pal; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2015-04-06       Impact factor: 2.671

Review 5.  In vitro reconstructed 3D corneal tissue models for ocular toxicology and ophthalmic drug development.

Authors:  Yulia Kaluzhny; Mitchell Klausner
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-02-05       Impact factor: 2.416

6.  Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.

Authors:  Rajendra S Kadam; Gajanan Jadhav; Miller Ogidigben; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2011-06-14       Impact factor: 3.922

7.  Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea.

Authors:  Sudharshan Hariharan; Mukul Minocha; Gyan P Mishra; Dhananjay Pal; Rohit Krishna; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2009-12       Impact factor: 2.671

8.  mRNA expression of metabolic enzymes in human cornea, corneal cell lines, and hemicornea constructs.

Authors:  Christian Kölln; Stephan Reichl
Journal:  J Ocul Pharmacol Ther       Date:  2011-12-23       Impact factor: 2.671

9.  Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor.

Authors:  Gangadhar Sunkara; Surya P Ayalasomayajula; Jack DeRuiter; Uday B Kompella
Journal:  Brain Res Bull       Date:  2009-09-15       Impact factor: 4.077

10.  Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier.

Authors:  Rajendra S Kadam; Robert I Scheinman; Uday B Kompella
Journal:  Mol Pharm       Date:  2012-10-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.